Value proposition

A Suisse start-up offering AI-enhanced oncology software to mitigate under-/overtreatment of women with breast cancer.

On target is fine. On goal is everything.

OncoGenomX is an ai-decision support solution (aiDSS) company known for its revolutionary approach to individualized drug-tumor matching, with the mission to end under- and overtreatment of patients, avoid expenditures for ineffective treatments, minimizing the risk of therapy failure and liability.

Our software (PredictionStar) enables prescription of more than 20 different anti-cancer drugs – biologically targeted, goal oriented, evidence-based, and applicable, for certainty of therapy success before starting treatment.

As the pioneers of biology-based drug-tumor matching and leader of reliable outcome prediction ahead of therapy start OncoGenomX is already a trusted name among breast cancer specialists. Working closely with oncologists, clinical researchers, international clinical study consortia and partner companies, OncogenomX is committed to game-changing software innovations - For optimal therapy of all tumors and all patients every time. For value-based cancer care, enabling longer, healthier, and better lives of people with cancer.

Do you want to be a part of an innovation that redefines clinical decision support?

We would love to hear from you and work together on creating an outcome and patient-oriented future.

For more information we invite you to watch our video https://youtu.be/yyYcZYi3XTk, or to contact us directly at info@oncogenomx.ch.


breast cancer, precision oncology, prediction software, molecular cancer diagnostics, digital imaging, digital pathology, clinical decision support, women's health, and femtech